Pharmaceutical Executive-11-01-2016

The industry is readying for a leap into a new age of complex therapies, as new heights are reached in fields such as regenerative cell-based therapies, CAR-T and immuno-oncology combinations. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality.

The steps to stay ahead of the looming shakeup in pharma.

Biopharma companies are increasingly leveraging product portfolios to own and dominate strategically important therapeutic areas.

An industry-based working group presents a common standards and definition framework for “Access” competencies in pharma-as a starting point in solving the current shortage of talent and leaders for this widening set of activities.

Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.

Pharm Exec sits down with Jeremy Desai, CEO of Apotex, Canada’s largest producer of generic drugs, to discuss the local impact of mounting pricing pressure-and how smaller and independent companies can survive in an era of consolidation and growing competition.

The influx of treatment breakthroughs and expanding science has not silenced the debate over the productivity of biopharma's R&D model, and the looming challenges for R&D decision-makers.

Cancer treatment is an increasing dilemma for EU health services as they try to balance patient care against budgetary constraints.

This year’s 19th annual European Health Forum Gastein (Austria) once again attempted to establish unity in the face of EU woes. But are the Gastein region’s “healing powers” on the wane?

Switzerland’s formidable pedigree as a pharmaceuticals powerhouse and hotbed of scientific innovation is often overlooked. But indeed these elements serve as major linchpins of the Swiss national economy, as the country continues to punch above its weight on the global stage for health affairs and medical-science advancement.

Click the title above to open the Pharmaceutical Executive November 2016 issue in an interactive PDF format.